Stimulation of Basal Secretion in the Treatment of Dry Eye Syndrome
https://doi.org/10.18008/1816-5095-2019-1-70-75
Abstract
The aim is to evaluate the effectiveness of Stillavit in the treatment of dry eye syndrome (DES) and its effect on the density of conjunctival goblet cells and the functional parameters of tear production. Methods. There were analyzed treatment results of 18 patients (36 eyes) with DES at the age of 48 to 80 years (average 60.6 ± 1.3 years) including 17 women and 1 male before and after 1 and 3 months after Stillavit prescription. In all patients in addition to a standard ophthalmological examination the results of Schirmer I, Norn, as well as the LIPCOF test were evaluated and the density of conjunctival goblet cells was examined. Results. After 1 and 3 months there was a significant improvement in the results of the Norn test: from 5.17 ± 0.22 seconds to 7.18 ± 0.17 seconds which indicated an increase in the stability of the tear film. After 3 months there was a significant increase in the density of conjunctival goblet cells, improvement in the Schirmer sample: from 9.26 ± 0.89 to 11.7 ± 0.6 mm (t = 2.28, p < 0.05) and LIPCOF test (t = 2.18, p < 0.05) which indicated an increase in tear production and a significant decrease in the inflammatory process and edema of the conjunctiva. Conclusion. Treatment of DES with the use of Stillavit leads after 3 months to a significant increase in the density of conjunctival goblet cells, increases tear production and stability of the tear film.
About the Authors
L. I. Uchakova
Volgograd branch of S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
PhD, head of the ophthalmology department of ambulatory surgery
Zemlyachki str., 80, Volgograd, 400138, Russia
S. V. Balalin
Volgograd branch of S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
MD, head of the scientific department
Zemlyachki str., 80, Volgograd, 400138, Russia
V. L. Zagrebin
Volgograd State Medical University
Russian Federation
Russian Federation
PhD, head of the department of histology, embryology and cytology
Pavshikh Bortsov Sq., 1, Volgograd, 400131, Russia
References
1. Brzheskiy V.V., Astakhov Yu.S., Kuznetsova N.Yu. Diseases of the lacrimal apparatus. Manual for practitioners. Saint Peterburg, 2009. 108 р. (in Russ.).
2. Brzheskiy V.V., Yegorova G.B., Yegorov Ye.A. Dry eye syndrome and ocular surface diseases: clinic, diagnosis, treatment. Moscow: GEOTAR-Media, 2016 (in Russ.).
3. Gayton J.L. Etiology, prevalence and treatment of dry eye disease. Clin. Ophthalmol. 2009;3:405–412. DOI: 10.2147/OPTH.S5555
4. Perry H.D. Dry eye disease: Pathophysiology, classification, and diagnosis. Am. J. Manag. Care. 2008;4(3). Suppl.:79–87.
5. Versura P., Profazio V., Giannaccare G., Fresina M., Campos E.C. Discomfort symptoms reduction and ocular surface parameters recovery with Artelac Rebalance treatment in mild-moderate dry eye. Eur. J. Ophthalmol. 2013;23(4):488–495. DOI: 10.5301/tjo.5000267
6. Yegorov Ye.A. Hyaluronic acid: application in ophthalmology and treatment of dry eye syndrome. Russian Medical Journal. Clinical Ophthalmology = Rossijskij medicinskij zhurnal. Klinicheskaya oftal’mologiya. 2013;2:71–73 (in Russ.).
7. Yeremenko A.I., Yanchenko S.V. The possibilities of using lymphotropic therapy in the treatment of dry eye syndrome. Russian Medical Journal. Clinical Ophthalmology = Rossijskij medicinskij zhurnal. Klinicheskaya oftal’mologiya. 2010;1:20 (in Russ.).
8. Tsubota K., Kawashima M., Inaba T. The antiaging approach for the treatment of dry eye. Cornea. 2012;31(1):3–8. DOI: 10.1097/ICO.0b013e31826a05a8
9. Mosunova Ye.P., Abramova T.V. Experience in using the Hilo-dresser solution of the Ursapharm company in the “dry eye” syndrome in the Kirov Regional Clinical Hospital. New in ophthalmology = Novoe v oftal’mologii. 2010;2:34–35 (in Russ.).
10. Teping Ch. Hyaluronsäure. Thieme Drug Report. 2010;4(2):1–12.
11. Daull P., Lallemand F., Garrigue J.S. Benefits of cetalkonium chloride cationic oilin-water nanoemulsions for topical ophthalmic drug delivery. J. Pharm. Pharmacol. 2014;66(4):531–541. DOI: 10.1111/jphp.12075
12. Lallemand F., Daull Ph., Benita S. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J. Drug Delivery. 2012; Article ID 604204:1–16. DOI: 10.1155/2012/604204
13. Brzheskiy V.V., Golubev S.Yu. The possibility of using hydroxypropylguar in tear replacement therapy. Annals of Ophthalmology = Vestnik oftal’mologii. 2017;133(1):88–96 (in Russ.). DOI: 10.17116/oftalma2017133188-96
14. Brzheskiy V.V., Efimova E.L., Vorontsova T.N. Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome. Advances in Therapy. 2015;32(12):1263–1279. DOI: 10.1007/s12325-015-0273-6
15. Luyckx J., Baudouin Ch. Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology. Clin. Ophthalmol. 2011;5:577–581. DOI: 10.2147/OPTH.S18827
16. Falkhut O.S., Polunina Ye.V. Rational approach in the diagnosis and treatment of dry eye syndrome. Medical Council = Medicinskij sovet. 2010;5–6:100–104 (in Russ.).
17. Kamiya K., Nakanishi M., Ishii R., Kobashi H., Igarashi A., Sato N., Shimizu K. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond). 2012;26:(10):1363–1368. DOI: 10.1038/eye.2012.166
18. Keating G.M. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye. Drugs. 2015;75:(8):911–922. DOI: 10.1007/s40265-015-0409-7
19. Toda I., Ide T., Fukumoto T., Ichihashi Y., Tsubota K. Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis. Am. J. Ophthalmol. 2014;157(3):616–622. DOI: 10.1016/j.ajo.2013.11.017
20. Argueso P., Balaram M., Spurr-Michaud S. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest. Ophthalmol. Vis. Sci. 2002;43:1004–1011.
Review
For citations:
Uchakova L.I., Balalin S.V., Zagrebin V.L. Stimulation of Basal Secretion in the Treatment of Dry Eye Syndrome. Ophthalmology in Russia. 2019;16(1):70-75. (In Russ.) https://doi.org/10.18008/1816-5095-2019-1-70-75
Views:
2229
Email this article 